JP2012527444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527444A5 JP2012527444A5 JP2012511367A JP2012511367A JP2012527444A5 JP 2012527444 A5 JP2012527444 A5 JP 2012527444A5 JP 2012511367 A JP2012511367 A JP 2012511367A JP 2012511367 A JP2012511367 A JP 2012511367A JP 2012527444 A5 JP2012527444 A5 JP 2012527444A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- compound according
- mir
- compound
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 235000000346 sugar Nutrition 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 108091007774 MIR107 Proteins 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 108091037473 miR-103 stem-loop Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000004110 gluconeogenesis Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18002409P | 2009-05-20 | 2009-05-20 | |
| US61/180,024 | 2009-05-20 | ||
| US32287810P | 2010-04-11 | 2010-04-11 | |
| US61/322,878 | 2010-04-11 | ||
| PCT/IB2010/001384 WO2010133970A1 (en) | 2009-05-20 | 2010-05-19 | Targeting micrornas for metabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015222848A Division JP6300775B2 (ja) | 2009-05-20 | 2015-11-13 | 代謝障害に関するターゲッティングマイクロｒｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527444A JP2012527444A (ja) | 2012-11-08 |
| JP2012527444A5 true JP2012527444A5 (enExample) | 2013-07-04 |
Family
ID=42563091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511367A Pending JP2012527444A (ja) | 2009-05-20 | 2010-05-19 | 代謝障害に関するターゲッティングマイクロｒｎａ |
| JP2015222848A Expired - Fee Related JP6300775B2 (ja) | 2009-05-20 | 2015-11-13 | 代謝障害に関するターゲッティングマイクロｒｎａ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015222848A Expired - Fee Related JP6300775B2 (ja) | 2009-05-20 | 2015-11-13 | 代謝障害に関するターゲッティングマイクロｒｎａ |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US8592388B2 (enExample) |
| EP (1) | EP2432880A1 (enExample) |
| JP (2) | JP2012527444A (enExample) |
| CN (2) | CN102459598B (enExample) |
| AU (2) | AU2010250838B2 (enExample) |
| CA (1) | CA2763016C (enExample) |
| WO (1) | WO2010133970A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010250838B2 (en) | 2009-05-20 | 2016-01-21 | Eth Zurich | Targeting microRNAs for metabolic disorders |
| WO2012027601A2 (en) * | 2010-08-25 | 2012-03-01 | The General Hospital Corporation | Methods targeting mir-33 micrornas for regulating lipid metabolism |
| EP2561102A1 (en) | 2010-12-02 | 2013-02-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Irak-related interventions and diagnosis |
| WO2012145374A1 (en) * | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
| WO2012174470A1 (en) * | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of pyruvate carboxylase expression |
| WO2013188879A1 (en) | 2012-06-16 | 2013-12-19 | Atherotech, Inc. | Measurement of serum lipoproteins |
| US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
| WO2014135653A1 (en) | 2013-03-06 | 2014-09-12 | Royal College Of Surgeons In Ireland | Diagnosis and treatment of metabolic disorders |
| WO2014150772A1 (en) * | 2013-03-15 | 2014-09-25 | The Johns Hopkins University | Methods for treating or preventing fatty liver disease using ctrp3 |
| WO2014201314A1 (en) | 2013-06-14 | 2014-12-18 | Joslin Diabetes Center, Inc. | Microrna and uses in brown fat differentiation |
| WO2015077503A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| US10704097B2 (en) | 2014-02-27 | 2020-07-07 | Katholieke Universiteit Leuven | Oxidative stress and cardiovascular disease events |
| DK3110973T3 (da) | 2014-02-27 | 2019-05-13 | Univ Leuven Kath | Oxidativt stress og kardiovaskulære sygdomshændelser |
| CN103940998B (zh) * | 2014-05-04 | 2016-04-20 | 山东大学 | 血清microRNA作为肝细胞癌转移的早期诊断标志物的应用 |
| RU2017105342A (ru) * | 2014-08-07 | 2018-09-13 | Регулус Терапьютикс Инк. | НАЦЕЛИВАНИЕ НА микроРНК ПРИ РАССТРОЙСТВАХ ОБМЕНА ВЕЩЕСТВ |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| CN105457028B (zh) * | 2014-09-04 | 2019-08-20 | 中国科学院上海生命科学研究院 | 在骨形成中发挥调控作用的应力敏感性microRNA |
| AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
| JP2018518169A (ja) * | 2015-06-05 | 2018-07-12 | レグルス セラピューティクス インコーポレイテッド | 非アルコール性脂肪肝疾患バイオマーカー |
| US10844383B1 (en) | 2019-09-18 | 2020-11-24 | Dasman Diabetes Institute | Microrna dyslipidemia inhibitor |
| CN112635018B (zh) * | 2020-12-24 | 2025-04-18 | 江苏精策医疗科技有限公司 | 一种提高无创血糖代谢热整合法检测的准确性的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340514A (zh) * | 2000-08-31 | 2002-03-20 | 上海博德基因开发有限公司 | 一种新的多肽——人U4/U6核内小RNA结合蛋白(U4/U6 sn RNP)13.09和编码这种多肽的多核苷酸 |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| FR2863640B1 (fr) * | 2003-12-16 | 2006-04-07 | Sinnoveg | Dispositif de haie defensive vegetale anti-intrusion et son procede de realisation |
| US20050261233A1 (en) * | 2004-04-21 | 2005-11-24 | Sanjay Bhanot | Modulation of glucose-6-phosphatase translocase expression |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP2314688B1 (en) | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| EP2388327A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| US8288356B2 (en) | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
| AU2010250838B2 (en) * | 2009-05-20 | 2016-01-21 | Eth Zurich | Targeting microRNAs for metabolic disorders |
-
2010
- 2010-05-19 AU AU2010250838A patent/AU2010250838B2/en not_active Ceased
- 2010-05-19 CN CN201080032062.0A patent/CN102459598B/zh not_active Expired - Fee Related
- 2010-05-19 US US13/320,873 patent/US8592388B2/en not_active Expired - Fee Related
- 2010-05-19 CA CA2763016A patent/CA2763016C/en not_active Expired - Fee Related
- 2010-05-19 CN CN201610302288.7A patent/CN105935365B/zh not_active Expired - Fee Related
- 2010-05-19 EP EP10724136A patent/EP2432880A1/en not_active Withdrawn
- 2010-05-19 WO PCT/IB2010/001384 patent/WO2010133970A1/en not_active Ceased
- 2010-05-19 JP JP2012511367A patent/JP2012527444A/ja active Pending
-
2013
- 2013-10-23 US US14/061,365 patent/US8877730B2/en not_active Expired - Fee Related
-
2014
- 2014-07-18 US US14/334,868 patent/US9243249B2/en not_active Expired - Fee Related
-
2015
- 2015-11-13 JP JP2015222848A patent/JP6300775B2/ja not_active Expired - Fee Related
- 2015-12-16 US US14/970,959 patent/US9550996B2/en not_active Expired - Fee Related
-
2016
- 2016-04-11 AU AU2016202224A patent/AU2016202224B2/en not_active Ceased
- 2016-12-12 US US15/375,433 patent/US9932595B2/en not_active Expired - Fee Related
-
2018
- 2018-02-20 US US15/900,169 patent/US10287589B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012527444A5 (enExample) | ||
| JP2012050439A5 (enExample) | ||
| JP2009506124A5 (enExample) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP2012050438A5 (enExample) | ||
| Van Rooij et al. | Toward microrna–based therapeutics for heart disease: The sense in antisense | |
| JP2013516489A5 (enExample) | ||
| JOP20200202A1 (ar) | اجسام مضادة بشرية لمستقبل الجلوكاجون | |
| JP2012029693A5 (enExample) | ||
| JP2013518605A5 (enExample) | ||
| JP2015502365A5 (enExample) | ||
| WO2010023327A4 (en) | Method for obtaining oligonucleotide aptamers and uses thereof | |
| JP2013501524A5 (enExample) | ||
| JP2011516410A5 (enExample) | ||
| NZ588185A (en) | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes | |
| IL300119A (en) | Oligonucleotides for inducing paternal ube3a expression | |
| JP2017509354A5 (enExample) | ||
| JP2016506240A5 (enExample) | ||
| JP2010535786A5 (enExample) | ||
| RU2016115782A (ru) | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) | |
| JP2010524486A5 (enExample) | ||
| WO2012051567A3 (en) | Obesity-related genes and their proteins and uses thereof | |
| JP2014503192A5 (enExample) | ||
| JP2015520170A5 (enExample) | ||
| JP2014530004A5 (enExample) |